Demographic, pre-bronchodilator and post-bronchodilator pulmonary function tests, blood inflammatory information among healthy subjects, patients with asthma and patients with chronic obstructive pulmonary disease (COPD)
| Healthy subjects (n=94§) | Patients with asthma (n=75) | Patients with COPD (n=215) | |
| Demography | |||
| Age (years) | 50.7 (17.2) | 48.7 (11.2) | 67.1 (7.2)†‡ |
| Female sex (%) | 59 | 47 | 41 |
| Body mass index (kg/m2) | 27.7 (5.5) | 33.5 (7.5)* | 27.9 (4.9)† |
| Race (white/African-American/other) (%) | 65/20/15 | 76/17/7 | 87/7/6‡ |
| Pre-bronchodilator | |||
| FEV1, %predicted | 98 (12) | 53 (14)* | 44 (18)†‡ |
| FVC, %predicted | 98 (10) | 69 (13)* | 76 (17) †‡ |
| FEV1/FVC | 79 (6) | 61 (11)* | 43 (13)†‡ |
| Post-bronchodilator | |||
| FEV1, %predicted | 103 (11) | 65 (11)* | 51 (19)†‡ |
| FVC, %predicted | 99 (10) | 80 (14)* | 85 (18)‡ |
| FEV1/FVC | 82 (6) | 65 (11)* | 45 (13)†‡ |
| Blood tests | |||
| Samples (n) | 93 | 73 | 213 |
| Total white blood cells (N/μL) | 5894 (1717) | 7902 (2962)* | 7247 (1999)‡ |
| Neutrophils (%) | 58.1 (7.8) | 59.2 (12.4) | 63.3 (9.7)‡ |
| Lymphocytes (%) | 31.7 (7.4) | 28.2 (10.5) | 24.6 (8.3)‡ |
| Eosinophils (%) | 2.3 (1.6) | 3.9 (3.7)* | 2.9 (1.8)‡ |
*P<0.01 for healthy versus asthmatic subjects.
†P<0.01 for asthmatic versus COPD subjects.
‡P<0.01 for COPD subjects versus healthy subjects.
§Healthy datasets contain 51 Severe Asthma Research Program and 43 SubPopulations and InteRmediate Outcome Measures In COPD Study subjects. Benjamini–Hochberg post-hoc tests were performed.
FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.